140 results
8-K
EX-10.1
RVLPQ
RVL Pharmaceuticals plc
20 Oct 23
Entry into a Material Definitive Agreement
5:00pm
Subsidiaries, including the notes thereto, audited by independent public accountants of recognized national standing and prepared in conformity … Collateral, and cause each provider of any such insurance to agree, by endorsement upon the policy or policies issued by it or by independent instruments
8-K
EX-4.2
becs4lzx92fnc
18 Aug 23
RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
4:06pm
8-K
EX-5.1
eyqnvtvr
18 Aug 23
RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
4:06pm
8-K
EX-4.4
d19p0k 96w
18 Aug 23
RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
4:06pm
8-K
EX-10.1
siwf13r qbgj1r
18 Aug 23
RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
4:06pm
8-K
EX-4.1
nmf85kqr51aw24
18 Aug 23
RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
4:06pm
8-K
EX-4.3
3bq4l38r528suwp9pq
18 Aug 23
RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
4:06pm
424B5
7cshfo1kgbe
17 Aug 23
Prospectus supplement for primary offering
4:05pm
8-K
9s9 d7rzp
16 Jun 23
Submission of Matters to a Vote of Security Holders
4:01pm
8-K
EX-99.1
o3tl8e79
18 Oct 22
RVL Pharmaceuticals plc Announces Preliminary Third Quarter 2022 UPNEEQ® Net Product Sales
7:11am